Trexject gets the tick from PBAC second time around


The Pharmaceutical Benefits Advisory Committee has approved pre-filled syringes for subcutaneous administration of methotrexate (Trexject) for the treatment of rheumatoid arthritis when oral methotrexate is unsuitable. The approval at their March meeting overturns a 2016 decision rejecting the application due to concerns about cost minimisation with the 50mg vial of methotrexate. However the latest decision ...


Already a member? Login to keep reading


OR
© 2017 the limbic